Odomzo OverviewSonidegib (INN), also known as LDE225 and marketed as Odomzo, is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) being developed as an anticancer agent by Novartis. Contents 1 Approvals and indications 2 Pharmacology 3 Development 4 Reference list Approvals and indications It was approved by the FDA for treating basal-cell carcinoma in July 2015 and is awaiting approval i...
Read more Odomzo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Sonidegib
Recent Odomzo Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 200mg
NDC Database Records for Odomzo: (2 results)Sorted by National Drug Code
- 0078-0645 Odomzo 200 mg Oral Capsule by Novartis Pharmaceuticals Corporation
- 47335-303 Odomzo 200 mg Oral Capsule by Sun Pharma Global Fze